Statin okozta mellékhatások - Tények és gének

Translated title of the contribution: Statin-induced adverse effects - Facts and genes

M. Harangi, Noémi Zsíros, Lilla Juhász, G. Paragh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Statin therapy is considered to be safe and rarely associated with serious adverse events. However, a significant proportion of patients on statin therapy show some degree of intolerance which can lead to decreased adherence to statin therapy. The authors summarize the symptoms, signs and frequencies of the most common statin-induced adverse effects and their most important risk factors including some single nucleotide polymorphisms and gene mutations. Also, they review the available approaches to detect and manage the statin-intolerant patients.

Original languageHungarian
Pages (from-to)83-92
Number of pages10
JournalOrvosi Hetilap
Volume154
Issue number3
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Genes
Signs and Symptoms
Single Nucleotide Polymorphism
Therapeutics
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Statin okozta mellékhatások - Tények és gének. / Harangi, M.; Zsíros, Noémi; Juhász, Lilla; Paragh, G.

In: Orvosi Hetilap, Vol. 154, No. 3, 01.01.2013, p. 83-92.

Research output: Contribution to journalArticle

Harangi, M. ; Zsíros, Noémi ; Juhász, Lilla ; Paragh, G. / Statin okozta mellékhatások - Tények és gének. In: Orvosi Hetilap. 2013 ; Vol. 154, No. 3. pp. 83-92.
@article{34941e994fdb4da39b17122efc8d6800,
title = "Statin okozta mell{\'e}khat{\'a}sok - T{\'e}nyek {\'e}s g{\'e}nek",
abstract = "Statin therapy is considered to be safe and rarely associated with serious adverse events. However, a significant proportion of patients on statin therapy show some degree of intolerance which can lead to decreased adherence to statin therapy. The authors summarize the symptoms, signs and frequencies of the most common statin-induced adverse effects and their most important risk factors including some single nucleotide polymorphisms and gene mutations. Also, they review the available approaches to detect and manage the statin-intolerant patients.",
keywords = "cytochrom P450, hepatopathy, intolerance, myopathy, statin",
author = "M. Harangi and No{\'e}mi Zs{\'i}ros and Lilla Juh{\'a}sz and G. Paragh",
year = "2013",
month = "1",
day = "1",
doi = "10.1556/OH.2013.29530",
language = "Hungarian",
volume = "154",
pages = "83--92",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - Statin okozta mellékhatások - Tények és gének

AU - Harangi, M.

AU - Zsíros, Noémi

AU - Juhász, Lilla

AU - Paragh, G.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Statin therapy is considered to be safe and rarely associated with serious adverse events. However, a significant proportion of patients on statin therapy show some degree of intolerance which can lead to decreased adherence to statin therapy. The authors summarize the symptoms, signs and frequencies of the most common statin-induced adverse effects and their most important risk factors including some single nucleotide polymorphisms and gene mutations. Also, they review the available approaches to detect and manage the statin-intolerant patients.

AB - Statin therapy is considered to be safe and rarely associated with serious adverse events. However, a significant proportion of patients on statin therapy show some degree of intolerance which can lead to decreased adherence to statin therapy. The authors summarize the symptoms, signs and frequencies of the most common statin-induced adverse effects and their most important risk factors including some single nucleotide polymorphisms and gene mutations. Also, they review the available approaches to detect and manage the statin-intolerant patients.

KW - cytochrom P450

KW - hepatopathy

KW - intolerance

KW - myopathy

KW - statin

UR - http://www.scopus.com/inward/record.url?scp=84872460762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872460762&partnerID=8YFLogxK

U2 - 10.1556/OH.2013.29530

DO - 10.1556/OH.2013.29530

M3 - Article

VL - 154

SP - 83

EP - 92

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 3

ER -